The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) （Children Forms of Drug）

Influenza Clinical Trial

Official title:

The Phase Ⅲ Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)（Children Forms of Drug）

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01551823
• Other study ID #: IMBCAMS-05
• Secondary ID: 2011L01487
• Status: Completed
• Phase: Phase 3
• Start date: March 2012
• Est. completion date: August 2012

Study information

• Verified date: October 2023
• Source: Institute of Medical Biology, Chinese Academy of Medical Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and the immunogenicity of Influenza Virus Vaccine (Split Virion, Inactivated)(children forms of drug) that do not contains Preservative.

Description:

Influenza Virus Vaccine (Split Virion, Inactivated) that do not contain Preservative. HA contents 7.5μg/0.5ml per dose include H1N1、H3N2 and B.

Inactivated Split Influenza Vaccine was manufactured by Sanofi Pasteur HA contents 7.5μg/0.5ml per dose include H1N1、H3N2 and B.

This is a randomized, blind phase 3 clinical trial. Total 1200 adults (ages from 6 months to 36 months ) were selected, randomized to two groups [Influenza Virus Vaccine (Split Virion, Inactivated) and Inactivated Split Influenza Vaccine , each group n=600], adults in each group will be vaccinated with two doses of either Influenza Virus Vaccine (Split Virion, Inactivated) or Sanof IVV respectively,21 days apart.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1200
• Est. completion date: August 2012
• Est. primary completion date: May 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Months to 35 Months

Eligibility

Inclusion Criteria:

• Males and females, age from 6 months to 35 months ;

• Adults, parent(s) or guardians are able to understand and sign informed consent for participation;

• Participants or guardians are able to attend all planned clinical appointment and obey and follow all study instructions;

• Infants no vaccinated with influenza or other preventive biologicals in recent 7 days;

• Axillary temperature =37?.

Exclusion Criteria:

• Have medical record of participants or their family on allergy and egg, convulsion, falling sickness, encephalopathy and psychopathy;

• Low platelet or bleeding disorder do not allow vaccination into the muscle;

• Have damaged or lower immunological function;

• Received blood, plasma or immunoglobulin treatment since birth; Have inborn abnormality, develop obstacles or clinical diagnostic serious chronic ( Down Syndrome, diabetes, sickle cell anemia or neural Guillain-Barre Syndrome );

• Have or be doubtful of following diseases: respiratory system diseases, acute infection or active chronic, cardiovascular diseases, liver and kidney diseases, skin diseases, HIV.

Exclusion Criteria for doses 2

• Have serious anaphylaxis or high fever, convulsion during first dose;

• Have any circus of Exclusion Criteria after Eligible for study;

• Have serious adverse event which related to previous vaccination;

• Withdrawal and Discontinuance Criteria;

• Received necessary or interference study drugs such as: immune-inhibition or immune-stimulating agents;

• Vaccinated with any other vaccine(except DTP);

• Stop observation determined by investigator owing to occurring serious adverse event.

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• Influenza Virus Vaccine(no Preservative )
Influenza Virus Vaccine(no Preservative) 2×0.25ml intramuscular injections
• Influenza Virus Vaccine(contains Preservative)
Influenza Virus Vaccine(contains Preservative)2×0.25ml intramuscular injections

Locations

Country	Name	City	State
China	Dingxing Center for Disease Prevention and Control	Shijiazhuang	Hebei

Sponsors (2)

Lead Sponsor	Collaborator
Institute of Medical Biology, Chinese Academy of Medical Sciences	Hebei Center for Disease Control and Prevention

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the safety and the immunogenicity of Influenza Virus Vaccine (Split Virion, Inactivated) (Children Forms of Drug)		six months

External Links

•   Home page of Institute of Medical Biology, Chinese Academy of Medical Sciences